- Drugs
- Friday, 22 May 2020
Hikma receives FDA approval for its generic Vascepa®
Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has announced that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is currently being appealed.
Brian Hoffmann, President of Generics said, "The approval for our generic version of Vascepa® is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need."
| Enquiries | |
| Hikma Pharmaceuticals PLC | |
| Susan Ringdal | +44 (0)20 7399 2760/ +44 7776 477050 |
| EVP, Strategic Planning and Global Affairs | |
| Steve Weiss | +1 732 720 2830/ +1 732 788 8279 |
| David Belian | +1 732 720 2814/+1 848 254 4875 |
| US Communications and Public Affairs |
Related Industry Updates
Pharmacovigilance (PV) and Drug Safety Software Market Growth Insights to 2027 by Top Players ARISGLOBAL, Ennov AB Cube, United BioSource, Sparta Systems
Sep 28, 2020
GSK sells $3.35 billion stake in Unilever’s Indian business
May 07, 2020
The ITC Complaint Against Estar Medical in the U.S. Is Withdrawn by Regenlab
Mar 05, 2020
Myopia Treatment Market is expected to reach US$ 19,571.85 million by 2030
Jan 10, 2024
Innovation Disrupting the Pricing of Drugs in Healthcare Industry
Jan 23, 2020
Europe pharmaceutical drug delivery market is expected to reach US$ 562,102.6 Mn by 2027
Oct 06, 2020
Clinical Trial Imaging Market is expected to reach US$ 2,480.32 million by 2028
May 23, 2023
Follow us on
